Phase II Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression.

Trial Profile

Phase II Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Oxytocin (Primary) ; Tibolone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Actual initiation date (Jan 2012 added as reported by ClinicalTrials.gov.
    • 02 Dec 2011 Planned end date changed from 1 Jan 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top